Post-Finasteride Syndrome: What the Evidence Really Shows

Post-finasteride syndrome (PFS) is the name given to sexual, mental and physical symptoms that some men report as persisting after they stop finasteride. Whether finasteride causes these lasting symptoms, and how often, is still unproven. What is established: finasteride modestly raises the risk of sexual side effects during treatment. In 2025 the European Medicines Agency (EMA) also confirmed suicidal thoughts as a side effect of finasteride tablets, with unknown frequency ^[1].

In short: Most men take finasteride without lasting problems, but the risks are real and should be discussed before starting. If you notice mood changes on finasteride 1 mg, stop and see a doctor. Topical finasteride and minoxidil are alternatives with less systemic exposure.

What is post-finasteride syndrome?

PFS describes a cluster of symptoms that men attribute to finasteride and that continue after stopping it:

• sexual: low libido, erectile dysfunction, ejaculation problems, reduced sensation
• mental: depression, anxiety, poor concentration, sometimes suicidal thoughts
• physical: fatigue, changes in muscle or skin, and other symptoms

A 2025 review concluded that men treated with finasteride could develop significant physical and psychological symptoms. It also noted that the research is contradictory, the mechanism is unclear, and the condition is not universally recognised ^[3]. Sceptics argue that PFS emerged mainly from uncontrolled, low-quality studies with strong selection bias. They point to a recognised nocebo effect in men who are told about possible side effects ^[4].

Both views agree on one thing: there is no diagnostic test, no agreed definition and no reliable estimate of how many users are affected.

Key studies at a glance

Study	Design	n	Result
Lee et al., Acta Derm Venereol 2019 [5]	Meta-analysis of 15 placebo-controlled RCTs	4,495	Finasteride 1 mg: relative risk of sexual dysfunction 1.66
Belknap et al., JAMA Dermatol 2015 [6]	Meta-analysis of safety reporting	34 trials	No trial had adequate safety reporting; 76% followed up for 1 year or less
Mondaini et al., J Sex Med 2007 [7]	Randomised, counselling vs none, 5 mg	120	Sexual side effects 43.6% if informed vs 15.3% if not
Nguyen et al., JAMA Dermatol 2021 [8]	WHO pharmacovigilance database	3,282 reports	Suicidality signal in men under 45 using it for hair loss
Welk et al., JAMA Intern Med 2017 [10]	Population cohort, men 66+	93,197 users	No increase in suicide; more self-harm and depression in first 18 months
Kim et al., Psychosom Med 2020 [11]	Population cohort, men 60+	51,466	No increased suicide risk
EMA PRAC review 2025 [1]	EU-wide review of all data	313 finasteride cases	Suicidal ideation confirmed as side effect of tablets

Sexual side effects in clinical trials

In placebo-controlled trials, finasteride clearly increases sexual side effects, but in absolute terms only a minority of men are affected. A meta-analysis of 15 double-blind trials with 4,495 men found a 1.57-fold risk of sexual dysfunction for 5-alpha reductase inhibitors overall, and 1.66-fold for finasteride 1 mg ^[5].

These trials may underestimate the problem. A 2015 analysis found that none of 34 finasteride hair-loss trials reported safety data adequately. Most followed patients for a year or less, and the pattern of results suggested sexual side effects were systematically under-detected ^[6]. Only 31% of real-world finasteride users would have qualified for the original trials ^[6].

The nocebo effect

What you expect can shape what you feel. In a classic trial, 120 men with an enlarged prostate received finasteride 5 mg without knowing what it was. Half were told it might cause sexual side effects. In that group, 43.6% reported sexual side effects, compared with 15.3% of those who were not told ^[7].

This doesn't mean side effects are imaginary. It shows that expectations, anxiety and online information can amplify symptoms. That makes it very hard to measure the true drug effect outside blinded trials.

Depression and suicidal thoughts

Drug safety databases

Reports to drug safety databases point to a signal, especially in younger men:

• In the WHO global database, finasteride showed a disproportionate number of reports of suicidality and psychological side effects. The signal was seen in men under 45 using it for hair loss, but not in older men using it for the prostate. The authors noted this could partly reflect increased reporting after media attention from 2012 onwards ^[8].
• A 2025 analysis of more than 35 million reports found strong signals for suicidality and depression with finasteride, but no suicidality signal for dutasteride. Symptoms were typically reported after about three to four months. The authors stress that this design cannot prove causation ^[9].

Population studies

Large cohort studies, mostly in older men, are more reassuring about suicide itself:

• In 93,197 men aged 66 or older in Canada, finasteride or dutasteride did not increase the risk of suicide. Self-harm and depression were more common in the first 18 months: about 17 and 237 extra cases per 100,000 patient-years ^[10].
• In 51,466 Korean men aged 60 or older, there was no increased suicide risk over seven years ^[11].
• A 2021 meta-analysis reported higher rates of depressive symptoms with finasteride than without (odds ratio 2.14) ^[12].

The EMA review (2025)

After an EU-wide review requested by France, the EMA's safety committee PRAC confirmed suicidal ideation as a side effect of finasteride 1 mg and 5 mg tablets ^[1]. Key points:

• Frequency unknown: 313 relevant finasteride cases were identified in the EU database, against an estimated exposure of around 270 million patient-years ^[1].
• Most cases involved the 1 mg dose used for hair loss ^[1].
• Men taking finasteride 1 mg who experience mood changes should stop treatment and seek medical advice ^[1].
• Sexual problems may contribute to mood changes, and a patient card is now included in 1 mg packs in the EU ^[1].
• No evidence linked finasteride skin spray to suicidal thoughts; dutasteride gets a precautionary warning ^[1].
• The benefits were judged to still outweigh the risks. The European Commission issued a binding decision in August 2025 ^[2].

Switzerland is not bound by EMA decisions. Check the current Swiss product information with your doctor or pharmacist.

Topical finasteride: a lower-exposure option

A finasteride spray applied to the scalp improved hair counts significantly versus placebo in a phase III trial of 458 men. Its effect was similar to oral finasteride. Peak blood levels of finasteride were more than 100 times lower, and DHT in the blood fell by 34.5% rather than 55.6% ^[13]. In a US adverse event database, signals for PFS-like symptoms were less frequent with topical than oral finasteride, although not absent ^[14].

What this means for you

Finasteride 1 mg remains one of the most effective treatments for male pattern hair loss ^[15]. In Switzerland it requires a prescription. Practical steps:

1. Before starting: tell your doctor about any history of depression, anxiety or sexual problems.
2. During treatment: if your mood drops, stop finasteride and see a doctor. In a crisis, call 143 (Die Dargebotene Hand) or 144.
3. Sexual side effects: discuss them early. Under the updated EU guidance, they are a reason to seek medical advice and to consider stopping ^[1].
4. Alternatives: minoxidil, oral minoxidil or topical finasteride.

Read our full finasteride guide for dosing and results.

How strong is the evidence?

• Sexual side effects during treatment: moderate evidence from RCTs, probably underestimated because of short, poorly reported trials ^[5,6].
• Persistent symptoms after stopping (PFS): weak evidence. Data come from case series, surveys and reports, with no control groups and strong selection bias. Its existence and frequency remain contested ^[3,4].
• Depression and suicidality: pharmacovigilance signals are consistent ^[8,9], but these data cannot prove causation and are affected by reporting bias. Cohort studies found no increase in suicide in older men ^[10,11]. The EMA nevertheless judged a causal link for suicidal thoughts to be established ^[1].
• Nocebo: shown in a randomised setting, but in older men taking 5 mg for the prostate ^[7].

Overall, the risks of finasteride are real but uncommon. Informed, monitored use is reasonable, but no one should feel pressured to take it. See our evidence overview for all treatment options.

When a hair transplant makes sense

If you prefer to avoid finasteride, a transplant can restore bald areas. Without medication, though, the native hair around the grafts may keep thinning, so planning must allow for future loss. Learn more in our hair transplant guide or compare providers in the clinic comparison.